**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 87685

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Depletion of gut microbiota facilitates fibroblast growth factor 21-mediated protection against acute pancreatitis in diabetic mice**

Sun QY *et al. FGF21* in AP diabetic mice

Qi-Yan Sun, Xu-Ye Wang, Zu-Pin Huang, Jing Song, En-Dong Zheng, Fang-Hua Gong, Xiao-Wang Huang

**Qi-Yan Sun, Xu-Ye Wang, Fang-Hua Gong,** School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China

**Qi-Yan Sun,** Zhejiang Medical Products Service Center, Hangzhou 310012,Zhejiang Province, China

**Zu-Pin Huang, Jing Song, En-Dong Zheng, Fang-Hua Gong, Xiao-Wang Huang,** Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cangnan Hospital of Wenzhou Medical University, Wenzhou 325800, Zhejiang Province, China

**Author contributions:** Sun QY, Wang XY and Huang ZP contributed equally to this work; Gong FH and Huang XW conceived the experiments, analyzed the data; Sun QY, Wang XY, Huang ZP, Song J and Zheng ED performed experiments, coordinated the study and oversaw all experiments, revised the paper; all authors discussed the results and commented on the manuscript.

**Supported by** the 2022 Zhejiang Provincial Health Science and Technology Plan, No. 2022KY1216.

**Corresponding author: Xiao-Wang Huang, MD, Chief Physician,** Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Cangnan Hospital of Wenzhou Medical University, No. 2288 Yucang Road, Lingxi Town, Wenzhou 325800, Zhejiang Province, China. hxw7@163.com

**Received:** August 22, 2023

**Revised:** September 28, 2023

**Accepted:** November 25, 2023

**Published online:** December 15, 2023

**Abstract**

BACKGROUND

Fibroblast growth factor 21 (*FGF21*), primarily secreted by the pancreas, liver, and adipose tissues, plays a pivotal role in regulating glucose and lipid metabolism. Acute pancreatitis (AP) is a common inflammatory disease with specific clinical manifestations. Many patients with diabetes present with concurrent inflammatory symptoms. Diabetes exacerbates intestinal permeability and intestinal inflammation, thus leading to the progression to AP. Our previous study indicated that FGF21 significantly attenuated susceptibility to AP in mice.

AIM

To investigate the potential protective role of *FGF21* against AP in diabetic mice.

METHODS

In the present study, a mouse model of AP was established in diabetic (db)/db diabetic mice through ceruletide injections. Thereafter, the protective effects of recombinant *FGF21* protein against AP were evaluated, with an emphasis on examining serum amylase (AMS) levels and pancreatic and intestinal inflammatory cytokines [interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and intestinal IL-1β]. Additionally, the impact of this treatment on the histopathologic changes of the pancreas and small intestinal was examined to elucidate the role of *FGF21* in diabetic mice with AP. An antibiotic (Abx) cocktail was administered in combination with *FGF21* therapy to investigate whether the effect of *FGF21* on AP in diabetic mice with AP was mediated through the modulation of the gut microbiota. Subsequently, the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), a bioinformatics software package, was used to predict different pathways between the groups and to explore the potential mechanisms by which the gut microbiota influenced the protective effect of *FGF21*.

RESULTS

The results indicated that *FGF21* notably diminished the levels of serum AMS (944.5 ± 15.9 *vs* 1732 ± 83.9, *P <* 0.01) and inflammatory factors including IL-6 (0.2400 ± 0.55 *vs* 1.233 ± 0.053, *P <* 0.01), TNF-α (0.7067 ± 0.22 *vs* 1.433 ± 0.051, *P <* 0.01), and IL-1β (1.377 ± 0.069 *vs* 0.3328 ± 0.02542, *P <* 0.01) in diabetic mice with AP. Moreover, notable signs of recovery were observed in the pancreatic structure of the mice. The histologic evidence of inflammation in the small intestine, including edema and villous damage, was significantly alleviated. *FGF21* also significantly altered the composition of the gut microbiota, reestablishing the *Bacteroidetes/Firmicutes* ratio. Upon treatment with an Abx cocktail to deplete the gut microbiota, the *FGF21* + Abx group showed lower levels of serum AMS (0.9328 ± 0.075 *vs* 0.2249 ± 0.023, *P <* 0.01) and inflammatory factors (1.083 ± 0.12 *vs* 0.2799 ± 0.032, *p <* 0.01) than the *FGF21* group. Furthermore, the *FGF21* + Abx group exhibited diminished injury to the pancreatic and small intestinal tissues, accompanied by a significant decrease in blood glucose levels (17.50 ± 1.1 *vs* 9.817 ± 0.69 mmol/L, *P <* 0.001). These findings underscored the superior protective effects of the combination therapy involving an Abx cocktail with *FGF21* over the *FGF21* treatment alone in diabetic mice with AP. The gut microbiota composition across different groups was further characterized, and a differential expression analysis of gene functions was undertaken using the PICRUSt2 prediction method. These findings suggested that *FGF21* could potentially confer therapeutic effects on diabetic mice with AP by modulating the sulfate reduction I pathway and the superpathway of n-acetylceramide degradation in the gut microbiota.

CONCLUSION

This study reveals the potential of *FGF21* in improving pancreatic and intestinal damage recovery, reducing blood glucose levels, and reshaping gut microbiota composition in diabetic mice with AP. Notably, the protective effects of *FGF21* are augmented when combined with the Abx cocktail.

**Key Words:** Acute pancreatitis; Fibroblast growth factor 21; Gut microbiota; Diabetes; PICRUSt2; Cocktail of antibiotics

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Sun QY, Wang XY, Huang ZP, Song J, Zheng ED, Gong FH, Huang XW. Depletion of gut microbiota facilitates fibroblast growth factor 21-mediated protection against acute pancreatitis in diabetic mice. *World J Diabetes* 2023; 14(12): 1824-1838

**URL**: https://www.wjgnet.com/1948-9358/full/v14/i12/1824.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v14.i12.1824

**Core Tip:** This study reveals the potential of facilitates fibroblast growth factor 21 (*FGF21*) in improving pancreatic and intestinal damage recovery, reducing blood glucose levels, and reshaping gut microbiota composition in diabetic mice with acute pancreatitis (AP). Notably, the protective effects of *FGF21* are augmented when combined with the Abx cocktail. These findings provide new insights into the prevention and treatment of diabetes complicated by AP.

**INTRODUCTION**

Acute pancreatitis (AP) is a local inflammatory disorder of the pancreas caused by aberrant activation of pancreatic proteases due to various contributing factors. The global annual incidence of AP is estimated to be approximately 34 cases per 100000 individuals, leading to many hospitalizations, high medical costs, and long-term sequelae for patients worldwide[1,2]. Diabetes is a chronic metabolic disorder caused by insufficient secretion or impaired action of insulin, leading to elevated blood glucose levels. Inflammation-related symptoms are commonly observed in many diabetic patients. Chronic inflammation is a complication of diabetes and other diseases, contributes to the occurrence and progression of diabetes and the associated conditions. The occurrence of diabetes has also been indicated to exacerbate the development of AP. Recent evidence further suggests that obesity aggravates the severity of AP, increases intestinal permeability, and facilitates intestinal inflammation[3]. Additionally, the analysis of the fecal microbiota composition revealed a reduction in the abundance of bacteria in obese rats with AP compared with rats with a normal body weight[4,5].

The imbalance in the gut microbiota composition and the reduction in microbial diversity in the intestine may lead to an increase in the pathogenic bacterial count and the disruption of cellular integrity. These alterations can contribute to an increase in intestinal leakage and permeability, leading to the subsequent development of intestinal inflammation and a reduction or disturbance in the immune response of the intestinal mucosa[6]. Prior research has highlighted that rats with type 2 diabetes and AP undergo changes in the structure of their gut microbiota, which increases the susceptibility to complex AP injury. It is interesting to note that fecal microbiota transplantation effectively mitigates intestinal mucosal injury and reduces inflammatory cell infiltration in mice[7]. Another study has proposed the prognosis of AP could be moderately facilitated through probiotic therapy[8]. Probiotic strains can enhance the production of interleukin (IL)-10, a pivotal regulatory and anti-inflammatory cytokine in diabetic mice. IL-10 suppresses pro-inflammatory cytokines, such as interferon-gamma and IL-2/IL-1β, thereby impeding the development of low-grade inflammation and diabetes[9,10].

Fibroblast growth factor 21 (*FGF21*), a recently identified metabolic regulator secreted by the liver, adipose tissue, and pancreas, has shown potent anti-inflammatory effects in animal experiments. It can downregulate the expression of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and IL-6[11]. Our preliminary research underscored a significant upregulation of *FGF21* expression in the context of AP. Exogenous administration of *FGF21* has been indicated to curtails pancreatic injury, aberrant expression of digestive enzymes, and inflammatory response, thus impeding the occurrence of AP[12]. However, it is important to further explore the potential of *FGF21* to ameliorate local or systemic inflammation and diminish blood glucose levels in mice with diabetes complicated by AP. Additionally, the involvement of the gut microbiota in the protective effects of *FGF21* in diabetic mice with AP warrants further investigation.

In the present study, a mouse model of AP was induced in diabetic (db)/db diabetic mice using ceruletide injections. The subsequent investigation focused on evaluating the protective effects of recombinant *FGF21* protein on serum amylase (AMS) and pancreatic and intestinal inflammatory cytokines (IL-6, TNF-α, and intestinal IL-1β). Additionally, we assessed the impact of this treatment on histopathologic changes in the pancreas and small intestine, aiming to enhance understanding of the role of *FGF21* in diabetic mice with AP. The study proceeded by administering a combination of *FGF21* therapy and an antibiotic (Abx) cocktail to assess the involvement of gut microbiota in the potential impact of *FGF21* on AP in diabetic mice. Subsequently, the application of Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), a bioinformatics software package, enabled us to predict different pathways between the groups. The objective was to explore the potential mechanisms by which the gut microbiota influenced the protective effect of *FGF21*.

**MATERIALS AND METHODS**

***Induction of AP in diabetic mice***

Male diabetic mice (db/db), aged 10 wk and weighing 40-55 g, were purchased from GemPharmatech Co., Ltd. (Nanjing, Jiangsu, China) and housed at the Experimental Animal Center of Wenzhou Medical University (Zhejiang, China). All experimental protocols involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and were approved by the Committee on Animal Health and Care of Wenzhou Medical University. Before the experiment, all animals were provided with a normal diet and allowed to acclimatize for 1 wk under a 12:12 Light-dark cycle at room temperature (23 ± 1°C) and approximately 60% humidity. Before AP modeling, the animals were subjected to a 12-h fasting period and had *ad libitum* access to drinking water.

Mice with fasting blood glucose levels > 16.7 mmol/L were regarded as diabetic mice and were randomly divided into the following groups (*n* = 5 per group): Diabetic mouse group (db), ceruletide-induced AP model group (AP), *FGF21* treatment group (*FGF21*), and *FGF21* combined with Abx cocktail treatment group (*FGF21* + Abx). AP model was established in mice of the AP, *FGF21*, and *FGF21* + Abx groups, wherein each mouse received seven intraperitoneal injections of ceruletide (50 μg/kg), at hourly intervals[13,14]. The mice in the db group received intraperitoneal injections of the same volume of normal saline as a control. The successful establishment of the AP mouse model was confirmed based on the following criteria: (1) Increased activity of serum AMS released from the pancreas, wherein the enzyme was detected using an enzyme-linked immunosorbent assay kit after AP induction; (2) no increase in pancreatic AMS levels; and (3) pancreatic tissues not meeting the diagnostic criteria for pancreatitis according to the modified Schmidt scoring system.

The animals were euthanized 6 h after the final injection of ceruletide. Serum and pancreatic and intestinal tissues were collected from mice of each group to determine the serum AMS levels and the ratio of pancreas weight to body weight. The collected tissues were embedded in paraffin, sliced, and stained with hematoxylin and eosin (HE), followed by a microscopic examination to observe the morphological changes in pancreatic tissues. 16S rRNA sequencing was performed to observe changes in the gut microbiota.

***FGF21 treatment***

Experimental mice in the *FGF21* and *FGF21* + Abx groups received an intraperitoneal injection of *FGF21* (1 mg/kg) 1 h before the ceruletide injection. In the same manner, mice from the db and AP groups received intraperitoneal injections of normal saline as a control.

***Abx cocktail treatment for diabetic mice with AP***

Mice in the *FGF21* + Abx group were orally administered with an Abx cocktail of non-absorbable Abx (ampicillin, neomycin, metronidazole, and vancomycin). The Abx cocktail was prepared at concentrations of 1 g/L, 1 g/L, 1 g/L, and 0.5 mg/L for each of these Abx, respectively. The Abx cocktail solution was freshly prepared every 2 d and administered continuously for 3 wk.

After 3 wk of Abx cocktail treatment, fecal samples were collected from mice in the *FGF21* + Abx group for fecal DNA extraction[13], followed by the detection of bacteria in the intestines using universal primers[14]. After depletion of the majority of bacteria in the mouse intestine, the mice in the *FGF21* + Abx group received an intraperitoneal injection of *FGF21*, followed by an intraperitoneal injection of ceruletide 1 h later to establish the AP model in diabetic mice.

***Immunoblotting assay***

Total protein was extracted from the pancreatic and intestinal tissues of mice, and the protein concentration was determined using a bicinchoninic acid assay. The protein samples were separated through sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). The membranes were then blocked with 10% skim milk–Tris-buffered saline with Tween 20 (TBST) solution at room temperature for 1.5 h, followed by an overnight incubation at 4 °C with the corresponding primary antibodies (IL-6 antibody diluted at 1:1000, IL-1β antibody diluted at 1:1000, TNF-α antibody diluted at 1:2000, β-actin antibody diluted at 1:5000, and GAPDH antibody diluted at 1:5000, all purchased from Proteintech). The membranes were rinsed with TBST solution in triplicate and then incubated with the corresponding secondary antibodies conjugated with horseradish peroxidase at room temperature for 1 h. Chemiluminescent signals were detected using the Tanon-5200 chemiluminescence imaging system. The signal from each protein band was quantified using the ImageJ software.

***Histological and immunohistochemical examinations***

Before histological analysis, mouse pancreatic and small intestinal tissues were fixed with 4% paraformaldehyde for more than 24 h. The fixed tissues were then embedded in paraffin, sliced at a thickness of 5 µm, and subjected to HE staining. The stained tissue sections were mounted with neutral resin and observed under a light microscope. The modified Schmidt scoring system was applied for the quantitative evaluation of pancreatic tissue damage.

***16S rRNA sequencing***

The diversity of the gut microbiota in clinical or laboratory animal samples was analyzed using 16S rRNA sequencing and the next-generation microbiome bioinformatics platform QIIME 2[15]. The latest version of the QIIME 2 platform, together with the DADA2 software package, was used to denoise the sequence data using approximately 100% similarity, with an operational taxonomic unit (OTU) clustering at 97% similarity[16]. Redundancy was then removed to obtain feature data (representative sequences) for comparison with the 16S database (132 version) and NT-16. This comparison aimed to identify and annotate all 16S rRNA sequences detected in the samples, including taxonomic categories of kingdom, phylum, class, order, family, genus, and species.

***Statistical analysis***

Statistical analysis of data was performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA). Data were presented as mean ± SEM. Statistical significance was determined using Student's *t*-test (for comparisons between two experimental conditions) or analysis of variance (ANOVA) (for comparisons among three or more experimental conditions). Pearson analysis was used to determine linear correlations between variables. A *P*-value of less than 0.05 was considered to indicate statistical significance.

**RESULTS**

***FGF21 significantly attenuates pancreatic injury and inflammation in diabetic mice with AP***

To investigate the impact of *FGF21* on AP in diabetic mice, we established an AP model in diabetic mice by administering ceruletide injections. Following the ceruletide injection, the ratio of pancreas weight to body weight of diabetic mice was notably reduced by approximately 22.1% (Figure 1A, *P <* 0.01). Serum levels of AMS in diabetic mice were found to be twice as high as those in the db group (Figure 1B, *P <* 0.01). Concurrently, the concentration of the inflammatory cytokine IL-6 in diabetic mice increased to five times of that in the db group (Figure 1C and D, *P <* 0.01), while the TNF-α level showed a significantly elevated to twice that of the db group (Figure 1C and E, *P <* 0.01). Following intraperitoneal injection of recombinant human *FGF21* protein, the *FGF21* group demonstrated an elevated ratio of pancreas weight to body weight, measuring at 19.3% (Figure 1A, *P <* 0.05). This result was accompanied by a reduction in the levels of serum AMS and inflammatory cytokines IL-6 and TNF-α (Figure 1C). Specifically, the serum levels of AMS decreased by 40.1% (Figure 1B, *P <* 0.001), IL-6 levels decreased by 24.4% (Figure 1D, *P <* 0.01), and TNF-α levels decreased to 65.1% of those in the AP group (Figure 1E, *P <* 0.05). Furthermore, diabetic mice with AP displayed pathological changes in pancreatic tissues, such as pancreatic edema, extensive intracellular vacuolation, and cellular necrosis (Figure 1F). Conversely, histological tissue sections of mice in the *FGF21* group exhibited a significant reduction in tissue damage (Figure 1F).

These findings highlight that ceruletide injections induce pancreatic injury and inflammation in diabetic mice, while *FGF21* treatment mitigates these symptoms in diabetic mice with AP.

***FGF21 treatment mitigates intestinal damage and improves the composition of gut microbiota***

To explore gut microbiota alterations in the context of AP, we assessed intestinal tissue damage in mice. The mice in the AP group showed exacerbated histologic evidence of inflammation in the small intestine, characterized by tissue edema, increased villus width, and villus damage (Figure 2A). After *FGF21* treatment, noticeable reductions in the levels of inflammatory factors were observed in the small intestinal tissue (Figure 2B), with TNF-α levels decreasing to 38.4% of that in the AP group (Figure 2C, *P <* 0.01), IL-6 levels decreasing by half (Figure 2D, *P <* 0.05), and IL-1β levels decreasing to 24.2% of that in the AP group (Figure 2E, *P <* 0.01), indicating a significant alleviation of intestinal tissue damage.

Next, 16S rRNA sequencing was performed to examine whether *FGF21* altered the composition of the gut microbiota in diabetic mice while alleviating intestinal damage. Principal coordinate analysis (PCoA) results demonstrated distinct segregation of the microbial communities among the db, AP, and *FGF21* groups, underscoring differences in the gut microbiota composition among the three groups (Figure 3A, *P <* 0.01). Alpha diversity of the gut microbiota, which serves as a comprehensive index of species abundance and evenness in community ecology, was assessed using four commonly used indices: observed OTUs, Chao1, Shannon, and Simpson indices. The observed OTUs and Chao1 indices reflect the species abundance in a sample, while the Shannon and Simpson indices reflect both the species abundance and evenness. When compared with the db group, all four indices showed significant increases in the AP group (*P <* 0.001). The *FGF21* group exhibited notable decreases in OTUs and Chao1 indices when compared with the AP group (*P <* 0.05), with Shannon and Simpson indices showing a nonsignificant decrease (Figure 3B-E). These results indicate an increase in gut microbiota abundance in diabetic mice with AP, and *FGF21* treatment could reverse this change. The gut microbiota plays a pivotal role in the occurrence of AP in diabetic mice.

We further compared the alterations in bacterial communities among the three groups, with the stacked bar chart illustrating bacterial species distribution and changes in species composition and distribution within each group. The experimental results highlighted distinct variations in the highest relative abundance of the top 30 species at different taxonomic levels of the samples. At the phylum level, *Firmicutes*, *Proteobacteria*, *Bacteroidetes*, and *Actinobacteria* emerged as major taxa in abundance across all samples (Figure 3F). Notably, phylum *Firmicutes* exhibited a marked elevation in the AP group (Figure 3G, *P <* 0.01), with significant decreases in the *FGF21* group (Figure 3G, *P <* 0.001). Meanwhile, phyla *Proteobacteria* and *Bacteroidetes* showed significant decreases in the AP group (Figure 3G, *P <* 0.05) and significant increases in the *FGF21* group (Figure 3G, *P <* 0.05). Moreover, *Firmicutes* was found to be the most abundant phylum across all samples. This study found that the *Bacteroides/Firmicutes* ratio decreased in the AP group, with a rebound in the *FGF21* group.

***Combined therapy of Abx cocktail and FGF21 significantly decreases the susceptibility to AP in diabetic mice***

Upon disrupting the gut microbiota through an Abx cocktail, a notable decrease in bacterial abundance was observed in the mouse feces (Figure 4A). Following the commencement of Abx cocktail treatment, the body weight of mice decreased, reaching the lowest point on day 13, with an average body weight of 45 g. However, following adaptation to the Abx cocktail feeding, the body weight of mice gradually increased and reached 48 g (Figure 4B). In subsequent experiments, when compared with the AP group, the *FGF21* + Abx group demonstrated a significant decrease in serum AMS levels (Figure 4C, *P <* 0.0001), with minimal damage observed in pancreatic and intestinal tissue sections (Figure 4D and E). Immunoblotting analysis revealed further reductions in the levels of the pro-inflammatory cytokines TNF-α and IL-6 in the *FGF21* + Abx group in the pancreatic tissue when compared with those in the *FGF21* group (Figure 4F). Specifically, TNF-α exhibited a significant decrease of 75.9% (Figure 4G, *P <* 0.01), and IL-6 showed a reduction to 25.8% of the *FGF21* + Abx group (Figure 4H, *P <* 0.01). Similarly, noticeable reductions in the levels of inflammatory factors were observed in the small intestinal tissue (Figure 4I), with TNF-α levels decreasing to 23.4% of that in the *FGF21* group (Figure 4J, *P <* 0.001), IL-1β levels decreasing by half (Figure 4K, *P <* 0.05), and IL-6 levels decreasing to 45.6% (Figure 4L, *P <* 0.01). Notably, blood glucose levels significantly decreased from 17.50 ± 1.1 to 9.817 ± 0.69 mmol/L (Figure 4F, *P <* 0.001) in the *FGF21* + Abx group, further decreasing from 15.14 ± 1.8 mmol/L in the *FGF21* group (Figure 4M, *P <* 0.05). These experimental results demonstrate that the combination therapy of Abx cocktail with *FGF21* exerts a more potent protective effect on AP in diabetic mice compared to *FGF21* treatment alone. The Abx cocktail enhances the protective efficacy of *FGF21* in diabetic mice with AP.

***Abx cocktail combined with FGF21 treatment alters microbiota in diabetic mice with AP***

To further investigate the contribution of the microbiota to the protective effects of *FGF21* in diabetic mice with AP, we compared the changes in bacterial communities among four groups of mice (Figure 5A and B). At the phylum level, *Firmicutes*, *Proteobacteria*, *Bacteroidetes*, and *Actinobacteria* were the major taxa of the bacterial communities across all four groups, accounting for 96.6% of the total abundance. In comparison with the db group, phylum *Firmicutes* showed a substantial increase to 66.2% in the AP group (Figure 5B, *P <* 0.01), while it decreased to 43.7% in the *FGF21* group, reaching normal levels, and further decreased to 5.7% in the *FGF21* + Abx group. Relative to the db group, phyla *Proteobacteria* and *Bacteroidetes* significantly decreased to 10.9% and 20.7%, respectively, in the AP group (Figure 5B, *P <* 0.05). After *FGF21* treatment, the abundance of *Proteobacteria* and *Bacteroidetes* significantly increased to 18.9% and 35.5%, respectively, in the *FGF21* group (Figure 5B, *P <* 0.05), reaching normal levels. In contrast, in the *FGF21* + Abx group, the phylum *Proteobacteria* significantly increased to 87.3% (Figure 5B, *P <* 0.001), while the phylum *Bacteroidetes* significantly decreased to 1.3% (Figure 5B, *P <* 0.001). Additionally, significant differences in gut microbiota composition were observed at the genus level among different groups (Figure 5C and D). The predominant taxa in the gut microbiota of the four groups of mice were *Lactobacillus*, *Mucispirillum-Klebsiella*, and *Escherichia coli*-*Shigella*, accounting for 44.3% in the *FGF21* + Abx group. Moreover, the AP group exhibited the highest abundance of *Lactobacillus*, accounting for 53%. In the *FGF21* + Abx group, *Escherichia coli-Shigella* accounted for 42%, while its abundance remained below 1% in the other three groups. Notably, prior research has highlighted an increase in the abundance of the phylum *Firmicutes* (gram-positive bacteria) and a decrease in the abundance of the phylum *Bacteroidetes* in obese mice[13]. After *FGF21* treatment, the proportion of *Firmicutes* was significantly reduced, while that of *Bacteroidetes* was significantly increased in diabetic mice with AP, underscoring the effectiveness of *FGF21* in alleviating diabetes conditions in diabetic mice with AP.

Through linear discriminant analysis (LDA) effect size (LEfSe), the biomarkers were compared among the four groups of samples. In this study, a threshold of > 4.5 LDA score and *P* < 0.05 were set for the LEfSe analysis. The variance in LDA scores across the four groups of microbiota samples revealed that the phylum *Proteobacteria*, order Enterobacteriales, and family Enterobacteriaceae were the most abundant species in the *FGF21* + Abx group. *Escherichia coli-Shigella* was found to be the most abundant species in the *FGF21* group. The phylum *Firmicutes*, class Clostridia, and order Clostridiales were most abundant in the db group. These bacteria may serve as potential targets for the treatment of diabetes complicated with AP. The order Lactobacillales, family Lactobacillaceae, and genus *Lactobacillus* were the most abundant in the AP group (Figure 5E). These bacteria belong to the class Bacilli. The phylogenetic tree in Figure 5F shows the origins of the microbiota at different taxonomic levels.

***Kyoto Encyclopedia of Genes and Genomes******analysis for the potential differential groups***

PICRUSt was used to predict the potential functions of microbial genes[17]. In this study, we adopted the PICRUSt2 prediction method to obtain gene function annotations from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Subsequently, statistical analysis of the metagenomic profiles (STAMP) was utilized for differential expression analysis[18] to identify significantly different gene functions among groups. Of note, the KEGG pathway database integrates current knowledge of molecular interaction networks, including biochemical processes such as metabolism, membrane translocation, signal transduction, cell cycle, and conserved subpathways in the same cell lineage.

The obtained findings suggested that the differential pathways (*P <* 0.05) between the *FGF21* + Abx group and the AP group included toluene degradation I (aerobic), toluene degradation III (aerobic), sulfate reduction I, cob(II) acetate a, c-diamine biosynthesis I, and the superpathway of n-acetylceramide degradation (Figure 6A). In addition, the differential pathways (*P <* 0.05) between the db and AP groups included histidine, purine, and pyrimidine biosynthesis, methoxy-13 biosynthesis, methoxy-12 biosynthesis, methoxy-11 biosynthesis, and methoxy-8 biosynthesis (Figure 6B). Furthermore, differential pathways (*P <* 0.05) between the db and *FGF21* + Abx groups included the superpathway of sulfate assimilation and cysteine biosynthesis, superpathway of L-alanine biosynthesis, glyoxylate cycle, tricarboxylic acid cycle I prokaryote, and fatty acid β-oxidation I (Figure 6C). These distinct differentially expressed pathways may provide critical insights into the effects of AP treatment.

**DISCUSSION**

AP is a clinically prevalent inflammatory disorder. Previous animal experiments have revealed the potential of *FGF21* to reduce the levels of digestive enzymes (AMS and lipase) in AP mice without affecting protein synthesis[19]. Additionally, *FGF21* has been demonstrated to diminish the release of inflammatory cytokines, such as TNF-α and IL-6, indicating a potent anti-inflammatory effect[11]. A previously reported study found that *FGF21* transgenic mice showed significant improvements in pancreatic inflammation and fibrosis in a model of AP induced by ceruletide[20]. In our previous study, it was revealed that *FGF21* exerted protective effects against AP through various mechanisms. These mechanisms included the stimulation of Sirt1 expression, the restoration of impaired mitochondria and lysosomes, the promotion of normal autophagic flux, and the suppression of aberrant expression of digestive enzymes in AP[12]. Furthermore, *FGF21* was found to reduce inflammatory responses, thereby contributing to the amelioration of AP. In the current study, *FGF21* treatment was found to ameliorate histopathological damage in the pancreatic tissues, reduce serum levels of AMS, and diminish levels of pro-inflammatory cytokines (IL-6 and TNF-α) in diabetic mice with AP. These results confirmed the potential of *FGF21* in decreasing the susceptibility to AP in diabetic mice. Moreover, both the *FGF21* group and the *FGF21*+Abx group showed a decline in blood glucose levels, indicating that *FGF21* and Abx cocktail therapy effectively alleviated both diabetes and AP in diabetic mice. These findings present a novel and enhanced pharmacological option for diabetic patients complicated by AP.

Notably, a previous comprehensive study was conducted using 16S rRNA sequencing technology to examine the bacteria associated with pancreatitis. It was found that 70% of patients with pancreatitis had various microbial DNA in their bloodstream[21]. The majority of these microbes exhibited similarity to those found in the gastrointestinal tract, suggesting a possible origin from the gut. Hence, we intended to explore whether the intestinal damage caused by diabetes and AP altered the composition of gut microbiota. To address this issue, the present study employed 16S rRNA sequencing technology to analyze the diversity of intestinal microbiota across three groups of mice. The analyses of beta and alpha diversity analyses revealed the differences in gut microbiota composition across the three groups. Notably, the AP group exhibited a significant increase in the abundance of gut microbiota of the AP group, which returned to normal levels after *FGF21* treatment. Prior research has established significant differences in the composition of gut microbiota between obese mice and wild-type mice. Specifically, obese mice showed a notable abundance of bacteria from the phylum *Firmicutes*, while wild-type mice displayed a predominant abundance of bacteria belonging to the phylum *Bacteroidetes*[22]. Furthermore, it has been identified that a decline in the *Bacteroides/Firmicutes* ratio is associated with obesity[23]. Thus, the current study conducted a comparative analysis of bacterial community changes in the mice of three groups, revealing a diminished *Bacteroides/Firmicutes* ratio in the AP group, which was increased after *FGF21* treatment. This finding suggests that AP exacerbates the changes in the gut microbiota of diabetic mice, and both AP and diabetes contribute to the increase in gut microbiota diversity and the decline in the *Bacteroides*/*Firmicutes* ratio. *FGF21* treatment effectively ameliorates the alterations in gut microbiota, thereby facilitating the alleviation of diabetes and AP conditions.

Subsequently, we sought to elaborate on whether the dysbiosis of gut microbiota in diabetic mice with AP was a concomitant phenomenon or an influencing factor in the occurrence and development of AP in diabetic mice. Our investigation also aimed to illuminate whether *FGF21* could ameliorate diabetes and AP condition through the modulation of the gut microbiota. The observations revealed a substantial protective effect of *FGF21* against pancreatitis and intestinal inflammation symptoms. Nonetheless, the effects of Abx on diabetes and systemic inflammation have been a subject of contentious debate in many studies. Some studies have reported the protective effect of Abx against diabetes and systemic inflammation, while in other studies, Abx has been shown to exacerbate the disease[24]. Previous studies have provided evidence demonstrating a reduction in the occurrence of diabetes in mice receiving vancomycin treatment from birth to weaning[25]. Moreover, prior research has also suggested that an Abx cocktail (sulfamethoxazole, trimethoprim, and streptomycin sulfate) lowered the occurrence of diabetes and delayed its onset[26]. The timing of Abx administration, particularly before the onset of diabetes onset in mice, can disrupt the balance of healthy gut microbiota, which in turn could provide an explanation for the increased occurrence of diabetes observed in most studies[27]. Notably, the responses of female and male mice to the same Abx treatments might be significantly different. Therefore, multiple variables, such as Abx type, dosage, administration timing, and the specific animal model, may significantly influence the efficacy of Abx treatment. In this study, the use of an Abx cocktail after the onset of diabetes reduced inflammation in the pancreas and small intestines. The administration of Abx to the mice was beneficial as it facilitated the elimination of harmful bacteria, thereby supporting the protective effect of *FGF21*. Although Abx administration may disrupt the gut microbiota and cause damage to the intestine, *FGF21* was reported to repair intestinal damage and effectively mitigate the adverse effects of Abx treatment on the intestine.

We also observed different microbial compositions in the db, AP, *FGF21*, and *FGF21* + Abx groups. Importantly, the AP group showed a notable increase in the abundance of *Lactobacillus*. *Lactobacillus*, as a probiotic, has been extensively studied. For instance, a recent study has highlighted the role of *Lactobacillus reuteri* in establishing a balanced gut microbiota, thereby mitigating the intestinal permeability damage caused by bacterial translocation. This probiotic also enhances the secretion of IgA in the ileum and colon and increases the populations of CD4+ and CD8+ cells. Thus, *Lactobacillus reuteri* shows promise in ameliorating methotrexate-induced enterocolitis[28]. In this study, the LEfSe analysis revealed that the most abundant taxa in the *FGF21* + Abx group were the phylum *Proteobacteria*, order Enterobacteriales, and family Enterobacteriaceae. The *FGF21* group was predominantly enriched with *Escherichia coli-Shigella*. In contrast, the phylum *Firmicutes*, class Clostridia, and order Clostridiales were most abundant in the db group. These bacteria may serve as targets for the treatment of AP under diabetic conditions. For instance, the deficiency of antimicrobial peptides, which exhibits a negative correlation with the abundance of *Escherichia coli* and *Shigella*, has been linked to intestinal barrier dysfunction and bacterial translocation[29]. *Enterobacter cloacae*, a common type of Bacteroides, can trigger inflammation and promote lipid accumulation, thus the development of metabolic diseases and atherosclerosis[30]. Dysbiosis of various gut probiotics is tightly associated with the progression of diabetes and AP. For instance, the reduction of *Faecalibacterium prausnitzii* abundance has been observed in the gut microbiota of individuals with intestinal diseases and type 2 diabetes has been observed[31,32].

The present study adopted the PICRUSt2 prediction method to obtain gene functional annotations from the KEGG database. In addition, STAMP was employed to perform differential expression analysis and identify gene functions that exhibit significant differences between groups. The identification of differential pathways may provide pivotal insights for AP treatment and unravel the mechanisms whereby gut microbiota modulates the therapeutic effects of *FGF21* on AP under diabetic conditions. Prior research has underscored a decrease in the levels of butyryl-CoA dehydrogenase in patients with diabetes relative to the control group, accompanied by a decrease in butyrate production in the gut microbiota[33]. In our study, *FGF21* + Abx treatment significantly facilitated the sulfate reduction pathway and inhibited the superpathway of n-acetylceramide degradation. These findings suggest significant differences when compared with the AP group and call for further investigation in subsequent studies.

**CONCLUSION**

This study revealed the potential ability of *FGF21* to enhance the recovery of pancreatic and intestinal damage recovery, reduce blood glucose levels, and modulate the composition of gut microbiota in diabetic mice with AP. Notably, the Abx cocktail therapy further influences the composition of the gut microbiota and enhances the protective effects of *FGF21*. These findings provide new insights into the prevention and treatment of diabetes complicated by AP. However, further investigation is required to elucidate the specific mechanisms by which the gut microbiota affects the protective effects of *FGF21* against AP in diabetic mice.

**ARTICLE HIGHLIGHTS**

***Research background***

Fibroblast growth factor 21 (*FGF21*) plays a pivotal role in regulating glucose and lipid metabolism. Acute pancreatitis (AP) is a common inflammatory disease with clinical manifestations. Diabetes exacerbates intestinal permeability and intestinal inflammation, thus leading to the progression to AP. Our previous study indicated that *FGF21* significantly attenuated susceptibility to AP in mice.

***Research motivation***

Yet, whether *FGF21* similarly protects AP in diabetic mice remains unexplored.

***Research objectives***

Herein, we were intrigued to investigate the potential protective role of *FGF21* against AP in diabetic mice.

***Research methods***

In the present study, a mouse model of AP was established in db/db diabetic mice through ceruletide injections. By comparing the differences in AP indicators between diabetic mouse group (db), ceruletide-induced AP model group (AP), *FGF21* treatment group (*FGF21*), and *FGF21* combined with an antibiotic (Abx) cocktail treatment group (*FGF21* + Abx), we investigated the protective effect of recombinant *FGF21* protein and investigated whether *FGF21* plays its role in the treatment of diabetic mice with AP by modulating the gut microbiota.

***Research results***

*FGF21* notably diminished the levels of serum amylase, inflammatory factors and the histological evidence of inflammation in the pancreas and the small intestine in diabetic mice with AP. *FGF21* also significantly altered the composition of the gut microbiota, reestablishing the *Bacteroidetes/Firmicutes* ratio. Upon treatment with an Abx cocktail to deplete the gut microbiota, the *FGF21* + Abx group showed superior protective effect. The gut microbiota composition across different groups was further characterized, and a differential expression analysis of gene functions was undertaken using the PICRUSt2 prediction method. These findings suggested that *FGF21* could potentially confer therapeutic effects on diabetic mice with AP by modulating the sulfate reduction I pathway and the superpathway of n-acetylceramide degradation in the gut microbiota.

***Research conclusions***

This study reveals the potential of *FGF21* in improving pancreatic and intestinal damage recovery, reducing blood glucose levels, and reshaping gut microbiota composition in diabetic mice with AP. Notably, the protective effects of *FGF21* are augmented when combined with the Abx cocktail. These findings provide new insights into the prevention and treatment of diabetes complicated by AP.

***Research perspectives***

Further investigation is required to elucidate the specific mechanisms by which the gut microbiota affects the protective effects of *FGF21* against AP in diabetic mice.

**REFERENCES**

1 **Petrov MS**, Yadav D. Global epidemiology and holistic prevention of pancreatitis. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 175-184 [PMID: 30482911 DOI: 10.1038/s41575-018-0087-5]

2 **Peery AF**, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. *Gastroenterology* 2019; **156**: 254-272.e11 [PMID: 30315778 DOI: 10.1053/j.gastro.2018.08.063]

3 **Ye C**, Liu L, Ma X, Tong H, Gao J, Tai Y, Huang L, Tang C, Wang R. Obesity Aggravates Acute Pancreatitis *via* Damaging Intestinal Mucosal Barrier and Changing Microbiota Composition in Rats. *Sci Rep* 2019; **9**: 69 [PMID: 30635594 DOI: 10.1038/s41598-018-36266-7]

4 **Lozupone CA**, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature* 2012; **489**: 220-230 [PMID: 22972295 DOI: 10.1038/nature11550]

5 **Cho I**, Blaser MJ. The human microbiome: at the interface of health and disease. *Nat Rev Genet* 2012; **13**: 260-270 [PMID: 22411464 DOI: 10.1038/nrg3182]

6 **Paun A**, Yau C, Danska JS. The Influence of the Microbiome on Type 1 Diabetes. *J Immunol* 2017; **198**: 590-595 [PMID: 28069754 DOI: 10.4049/jimmunol.1601519]

7 **Li M**, Liang P, Li Z, Wang Y, Zhang G, Gao H, Wen S, Tang L. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. *Front Microbiol* 2015; **6**: 692 [PMID: 26217323 DOI: 10.3389/fmicb.2015.00692]

8 **Oláh A**, Belágyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg* 2002; **89**: 1103-1107 [PMID: 12190674 DOI: 10.1046/j.1365-2168.2002.02189.x]

9 **Sanz Y**, Rastmanesh R, Agostoni C. Understanding the role of gut microbes and probiotics in obesity: how far are we? *Pharmacol Res* 2013; **69**: 144-155 [PMID: 23147032 DOI: 10.1016/j.phrs.2012.10.021]

10 **Cano PG**, Santacruz A, Trejo FM, Sanz Y. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. *Obesity (Silver Spring)* 2013; **21**: 2310-2321 [PMID: 23418126 DOI: 10.1002/oby.20330]

11 **Levine B**, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008; **132**: 27-42 [PMID: 18191218 DOI: 10.1016/j.cell.2007.12.018]

12 **Chen Q**, Li J, Ma J, Yang X, Ni M, Zhang Y, Li X, Lin Z, Gong F. Fibroblast growth factor 21 alleviates acute pancreatitis *via* activation of the Sirt1-autophagy signalling pathway. *J Cell Mol Med* 2020; **24**: 5341-5351 [PMID: 32233059 DOI: 10.1111/jcmm.15190]

13 **Pandol SJ**, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. *Gastroenterology* 2007; **132**: 1127-1151 [PMID: 17383433 DOI: 10.1053/j.gastro.2007.01.055]

14 **Everhart JE**, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. *Gastroenterology* 2009; **136**: 1134-1144 [PMID: 19245868 DOI: 10.1053/j.gastro.2009.02.038]

15 **Bolyen E**, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR, Keim P, Kelley ST, Knights D, Koester I, Kosciolek T, Kreps J, Langille MGI, Lee J, Ley R, Liu YX, Loftfield E, Lozupone C, Maher M, Marotz C, Martin BD, McDonald D, McIver LJ, Melnik AV, Metcalf JL, Morgan SC, Morton JT, Naimey AT, Navas-Molina JA, Nothias LF, Orchanian SB, Pearson T, Peoples SL, Petras D, Preuss ML, Pruesse E, Rasmussen LB, Rivers A, Robeson MS 2nd, Rosenthal P, Segata N, Shaffer M, Shiffer A, Sinha R, Song SJ, Spear JR, Swafford AD, Thompson LR, Torres PJ, Trinh P, Tripathi A, Turnbaugh PJ, Ul-Hasan S, van der Hooft JJJ, Vargas F, Vázquez-Baeza Y, Vogtmann E, von Hippel M, Walters W, Wan Y, Wang M, Warren J, Weber KC, Williamson CHD, Willis AD, Xu ZZ, Zaneveld JR, Zhang Y, Zhu Q, Knight R, Caporaso JG. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol* 2019; **37**: 852-857 [PMID: 31341288 DOI: 10.1038/s41587-019-0209-9]

16 **Callahan BJ**, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat Methods* 2016; **13**: 581-583 [PMID: 27214047 DOI: 10.1038/nmeth.3869]

17 **Douglas GM**, Maffei VJ, Zaneveld J, Yurgel SN, Langille MGI. PICRUSt2: An improved and extensible approach for metagenome inference. 2020 Preprint. Available from: bioRxiv:672295 [DOI: 10.1101/672295]

18 **Parks DH**, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics* 2014; **30**: 3123-3124 [PMID: 25061070 DOI: 10.1093/bioinformatics/btu494]

19 **Wang S**, Wang Y, Zhang Z, Liu Q, Gu J. Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity *via* the SIRT1/LKB1/AMPK pathway. *Cell Death Dis* 2017; **8**: e3018 [PMID: 28837153 DOI: 10.1038/cddis.2017.410]

20 **Fortunato F**, Bürgers H, Bergmann F, Rieger P, Büchler MW, Kroemer G, Werner J. Impaired autolysosome formation correlates with Lamp-2 depletion: role of apoptosis, autophagy, and necrosis in pancreatitis. *Gastroenterology* 2009; **137**: 350-360, 360.e1-360.e5 [PMID: 19362087 DOI: 10.1053/j.gastro.2009.04.003]

21 **Li Q**, Wang C, Tang C, He Q, Li N, Li J. Bacteremia in patients with acute pancreatitis as revealed by 16S ribosomal RNA gene-based techniques\*. *Crit Care Med* 2013; **41**: 1938-1950 [PMID: 23863226 DOI: 10.1097/CCM.0b013e31828a3dba]

22 **Turnbaugh PJ**, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; **444**: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]

23 **Ley RE**, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006; **444**: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]

24 **Brown K**, Godovannyi A, Ma C, Zhang Y, Ahmadi-Vand Z, Dai C, Gorzelak MA, Chan Y, Chan JM, Lochner A, Dutz JP, Vallance BA, Gibson DL. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. *ISME J* 2016; **10**: 321-332 [PMID: 26274050 DOI: 10.1038/ismej.2015.114]

25 **Hansen CH**, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sørensen SJ, Buschard K, Hansen AK. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. *Diabetologia* 2012; **55**: 2285-2294 [PMID: 22572803 DOI: 10.1007/s00125-012-2564-7]

26 **Brugman S**, Klatter FA, Visser JT, Wildeboer-Veloo AC, Harmsen HJ, Rozing J, Bos NA. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? *Diabetologia* 2006; **49**: 2105-2108 [PMID: 16816951 DOI: 10.1007/s00125-006-0334-0]

27 **Lee JG**, Eun CS, Jo SV, Lee AR, Park CH, Han DS. The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model. *PLoS One* 2019; **14**: e0226907 [PMID: 31860645 DOI: 10.1371/journal.pone.0226907]

28 **Zhang P**, Meng X, Li D, Calderone R, Mao D, Sui B. Commensal Homeostasis of Gut Microbiota-Host for the Impact of Obesity. *Front Physiol* 2017; **8**: 1122 [PMID: 29358923 DOI: 10.3389/fphys.2017.01122]

29 **Teltschik Z**, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, Bevins CL, Stange EF, Wehkamp J. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. *Hepatology* 2012; **55**: 1154-1163 [PMID: 22095436 DOI: 10.1002/hep.24789]

30 **Jin M**, Zheng L, Wei Y, Cheng J, Zhang D, Yan S, Qin H, Wang Q, Ci X, Feng H. Enterobacter cloacae aggravates metabolic disease by inducing inflammation and lipid accumulation. *Environ Toxicol Pharmacol* 2022; **90**: 103819 [PMID: 35077907 DOI: 10.1016/j.etap.2022.103819]

31 **Qin J**, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* 2012; **490**: 55-60 [PMID: 23023125 DOI: 10.1038/nature11450]

32 **Miquel S**, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. *Curr Opin Microbiol* 2013; **16**: 255-261 [PMID: 23831042 DOI: 10.1016/j.mib.2013.06.003]

33 **Brown CT**, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz D, Atkinson MA, Triplett EW. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. *PLoS One* 2011; **6**: e25792 [PMID: 22043294 DOI: 10.1371/journal.pone.0025792]

**Footnotes**

**Institutional review board statement:** This study did not involve human experimentation.

**Institutional animal care and use committee statement:** The study was reviewed and approved by the Ethics Committee of the Laboratory Animal of Wenzhou Medical University Institutional Review Board (Approval No.xmsq2023-0426).

**Conflict-of-interest statement:** The author declare that there is no conflict of interest regarding the publication of this manuscript.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 22, 2023

**First decision:** September 18, 2023

**Article in press:** November 25, 2023

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): D, D, D


Grade E (Poor): 0

**P-Reviewer:** Kitamura K, Japan; Susak YM, Ukraine; Lu Cai, United States **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Chen YX


**Figure Legends**




**Figure 1** **Fibroblast growth factor 21 significantly attenuates pancreatic injury and inflammation in diabetic mice with acute pancreatitis.** A: The ratio of pancreas weight to body weight of mice in diabetic (db), acute pancreatitis (AP) and fibroblast growth factor 21 (*FGF21*) groups; B: Serum levels of amylase of mice in db, AP and *FGF21* groups; C-E: Representative immunoblots of inflammatory factors in mouse pancreatic tissue. Expression levels of interleukin-6 and tumor necrosis factor-alpha were quantified using densitometry, with GAPDH as a protein loading control; F: Pathological changes in pancreatic tissues of mice in db, AP and *FGF21* groups, such as pancreatic edema, extensive intracellular vacuolation, and cellular necrosis (scale bar: 100 µm). Data are presented as mean ± SD, a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. AP: Acute pancreatitis; AMS: Amylase; db: Diabetic; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha; *FGF21*: Fibroblast growth factor 21.




**Figure 2** **Fibroblast growth factor 21 treatment mitigates intestinal damage and inflammation in diabetic mice with acute pancreatitis.** A: Histological changes in the small intestine of mice in diabetic, acute pancreatitis and fibroblast growth factor 21 groups, characterized by tissue edema, increased villus width, and villus damage (scale bar: 100 µm); B-E: Representative immunoblots of inflammatory factors in mouse small intestinal tissue. Expression levels of interleukin-6 and tumor necrosis factor-alpha were quantified using densitometry, with GAPDH as a protein loading control. Data are presented as mean ± SD, a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. AP: Acute pancreatitis; db: Diabetic; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha; *FGF21*: Fibroblast growth factor 21.




**Figure 3** **Fibroblast growth factor 21 treatment improves the composition of gut microbiota.** A: Principal coordinate analysis results demonstrated distinct segregation of the microbial communities among the diabetic (db), acute pancreatitis (AP), and fibroblast growth factor 21 (*FGF21*) groups. Different colors in the scatter plots represent samples from different groups; the higher the similarity between samples, the closer they are in the plots; B-E: The observed operational taxonomic units, Chao1, Shannon, and Simpson indices of the gut microbiota of db, AP and *FGF21* group mice. All four indices increased in the AP group compared with the db group, and the *FGF21* group exhibited decreases compared with the AP group; F: Bar graph of the structural distributions of fecal microbial communities at the phylum level; G: Relative abundance of the dominant phyla. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001, d*P* < 0.0001. AP: Acute pancreatitis; db: Diabetic; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha; *FGF21*: Fibroblast growth factor 21.



**Figure 4** **Combined therapy of Abx cocktail and fibroblast growth factor 21 significantly decreases the susceptibility to acute pancreatitis in diabetic mice.** A: Verification of the intestinal microbiota removal after feeding antibiotics; B: Following Abx cocktail treatment initiation, the body weight change of mice; C: Serum amylase levels of mice in each group; D: Pathological changes in pancreatic tissues of mice in each group, such as pancreatic edema, extensive intracellular vacuolation, and cellular necrosis (scale bar: 100 µm); E: Histological changes in the small intestine of mice in each group, characterized by tissue edema, increased villus width, and villus damage (scale bar: 100 µm); F-H: Representative immunoblots of inflammatory factors in mouse pancreatic tissue. Expression levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha were quantified using densitometry, with GAPDH as a protein loading control; I-L: Representative immunoblots of inflammatory factors in mouse small intestinal tissue. Expression levels of IL-6, TNF-α and IL-1β were quantified using densitometry, with GAPDH as a protein loading control. M: Changes in blood glucose in mice in different groups. Data are presented as mean ± SD, a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. AP: Acute pancreatitis; db: Diabetic; IL: Interleukin; TNF-α: Tumor necrosis factor-alpha; *FGF21*: Fibroblast growth factor 21.



**Figure 5** **Abx cocktail combined with fibroblast growth factor 21 treatment alters microbiota in diabetic mice with acute pancreatitis.** A: Bar graph of the structural distributions of fecal microbial communities at the phylum level; B: Relative abundance of the dominant phyla; C: Bar graph of the structural distributions of fecal microbial communities at the genus level; D: Relative abundance of the dominant genera; E: Linear discriminant analysis (LDA) scores for the differentially abundant bacterial taxa between each group (LDA > 4.5); F: The phylogenetic tree shows the origins of the microbiota at different taxonomic levels. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001. AP: Acute pancreatitis; db: Diabetic; *FGF21*: Fibroblast growth factor 21.



**Figure 6 The significantly different gene functions among groups.** A: The differential pathways between the fibroblast growth factor 21 (*FGF21*) + Abx group and the acute pancreatitis (AP) group; B: The differential pathways between the diabetic (db) and AP groups; C; The differential pathways between the db and *FGF21* + Abx groups. AP: Acute pancreatitis; db: Diabetic; *FGF21*: Fibroblast growth factor 21.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**